The results? A nasal spray of oxytocin significantly reduced acute feelings of loneliness in participants, especially during group therapy sessions, even months after treatment. In the study ...
The U.S. Food and Drug Administration (FDA) has approved the use of a nasal spray as a standalone treatment for major depressive disorder, offering a new option for those struggling with treatment ...
Now, the Food and Drug Administration (FDA) has expanded approval for Johnson & Johnson's nasal spray, Spravato, to be used as a standalone treatment for people with severe depression who haven't ...
The nasal spray can be given to people who haven’t seen improvements in their depression after taking at least two oral medications, according to Johnson & Johnson. The main ingredient for the ...
For patients with allergic rhinitis, twice-daily azelastine plus fluticasone cut nasal symptoms ... all treatments were administered as one spray twice daily to preserve blinding.
Total symptom scores, nasal obstruction, and doctor and patient perception of improvement were measured as markers of disease severity. Results: Although not statistically significant, both ...
A ketamine-based nasal spray is officially the first and only standalone therapy available for treatment-resistant depression in the US. The FDA first approved the Johnson & Johnson drug, called ...
When the sinuses and nasal passages become inflamed, it’s known as sinusitis. Inflammation can occur because of conditions such as structural issues in the nose or a sinus infection. The terms ...
A one-time nasal spray has been approved by the Food and Drug Administration as a standalone treatment for depression. The drug made by Johnson & Johnson under the brand name Spravato passed final ...
Johnson & Johnson's nasal spray received US FDA approval The nasal spray is used for the treatment of major depressive disorder The drug brought in sales of $780 million in 2024 The US Food and Drug ...
Got a tip? Send it to The Daily Beast here. ADVERTISEMENT ADVERTISEMENT ...